Pharmacological AMPK activators, such as 5-aminoimidazole-4-carboxamide (AICA) riboside, ameliorate insulin resistance in rodent models5,17,18, although poor bioavailability limits their biological effects in vivo. Here, PRKAB1 is linked to Insulin resistance.